FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 73 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC May 15, 2023 Young Women At Increased Risk Of Aggressive Breast Cancer January 21, 2022 ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 Aggressive Prostate Cancer Subtype More Common Than Expected July 31, 2018 Load more HOT NEWS RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations... Preoperative ctDNA Levels Are Detectable in the Majority of Patients with... Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... Bra Straps with Disappearing Message Remind Women to Check Their Breasts...
